Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16369976 | 1.00 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2USP2NR1H2RXRA | |
| SCHEMBL905280 | 1.00 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2USP2NR1H2RXRA | |
| SCHEMBL23545844 | 0.91 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2USP2HPGDHSD11B1 | |
| SCHEMBL29805394 | 0.91 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2USP2HPGDHSD11B1 | |
| SCHEMBL16409169 | 0.87 | USP2 (0.37) | HSD17B10SMN1; SMN2USP2NR1H2RXRA | |
| SCHEMBL16409170 | 0.87 | USP2 (0.37) | HSD17B10SMN1; SMN2USP2NR1H2RXRA | |
| SCHEMBL7456496 | 0.87 | DPP4 (0.38) | HSD17B10SMN1; SMN2NR1H2RXRANR1H3 | |
| SCHEMBL7456493 | 0.87 | DPP4 (0.38) | HSD17B10SMN1; SMN2NR1H2RXRANR1H3 | |
| SCHEMBL8337375 | 0.84 | NR1H2 (0.36) | HSD17B10SMN1; SMN2USP2NR1H2NR1H3 | |
| SCHEMBL883204 | 0.84 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2USP2NR1H2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12486269-B2 | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity | ACONCAGUA BIO, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250257067-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO, INC. | 2025-08-14 | — | — | US | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| EP-2995615-A1 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND THEIR PHARMACEUTICAL USE | AstraZeneca AB (SE) | 2016-03-16 | — | — | EP | disclosed |
| EP-2272825-B1 | Protected amino hydroxy adamantane carboxylic acid and process for its preparation | ASTRAZENECA AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| US-6515011-B2 | Anticoagulants | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1261586-A2 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | Bristol-Myers Squibb Company (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1202626-A4 | ALPHA-HYDROXY-GAMMA-[[(CARBOCYCLIC-OR HETEROCYCLIC-SUBSTITUTED)AMINO]CARBONYL]ALKANAMIDE DERIVATIVES AND USES THEREOF | MERCK & CO INC (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020119992-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002064559-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| US-6395767-B2 | ANTIDIABETIC AGENTS; SAXAGLIPTIN | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-28 | — | — | US | disclosed |
| EP-1202626-A1 | ALPHA-HYDROXY-GAMMA-[[(CARBOCYCLIC-OR HETEROCYCLIC-SUBSTITUTED)AMINO]CARBONYL]ALKANAMIDE DERIVATIVES AND USES THEREOF | Merck & Co., Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| US-20020019411-A1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | US | disclosed |
| WO-2001068603-A2 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL IV, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | BRISTOL-MYERS SQUIBB CO. (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001005230-A1 | ALPHA-HYDROXY-GAMMA-[[(CARBOCYCLIC-OR HETEROCYCLIC-SUBSTITUTED)AMINO]CARBONYL]ALKANAMIDE DERIVATIVES AND USES THEREOF | MERCK & CO., INC. (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486269-B2 | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity | IAPP, GIPR, SCTR | HSD17B10 2972/4885SMN1; SMN2 1394/4885USP2 2812/4885 |
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | NPY1R, CALCRL, SCTR | HSD17B10 1059/4885SMN1; SMN2 741/4885USP2 3498/4885 |
| US-20250257067-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | IAPP, GIPR, SCTR | HSD17B10 2972/4885SMN1; SMN2 1394/4885USP2 2812/4885 |
| US-20020019411-A1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | DPP4, DPP3, DPP7 | HSD17B10 358/4885SMN1; SMN2 3749/4885USP2 2118/4885 |
| US-20020119992-A1 | Thrombin inhibitors | SERPINC1, F2, TFPI | HSD17B10 1231/4885SMN1; SMN2 4400/4885USP2 2471/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | HSD17B10 2646/4885SMN1; SMN2 4657/4885USP2 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.